Bristol Myers Squibb Reports Q4 Earnings

Trade BMY Shares Your Capital Is At Risk
Analyst Team
Updated: 4 Feb 2022

Key points:

Bristol Myers Squibb (NYSE: BMY) announced an earnings per share of $1.83 before the bell on Friday, with revenue coming in at $11.99 billion.

new-recommended-broker-banner

The numbers reported were against an anticipated EPS of $1.80 and revenue of $12.04 billion.

The company's U.S. revenues increased 11% to $7.5 billion in the quarter, while international revenues increased 4% to $4.5 billion.

Also Read: The Best Monthly Dividend Stocks Under $10

In reaction to the report, BMY's share price has moved 0.5% to $64.40.

“2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio,” said Giovanni Caforio, CEO of Bristol Myers Squibb.

“I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib.”

The company sees full-year 2022 adjusted EPS between $7.65 and $7.95. BMY expects worldwide revenues to be approximately $47 billion, representing an increase in the low-single digits.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .